Metastatic Breast Cancer

Oncology·MeSH: Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

47 drugs in development·23 companies·59 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
Aybintio (SB8)	Organon & Co. (OGN)
cerianna	GE HealthCare Technologies Inc. (GEHC)
doxorubicin	Amneal Pharmaceuticals, Inc. (AMRX)
eribulin	DR REDDYS LABORATORIES LTD (RDY)
ibrance	PFIZER INC (PFE)
Inluriyo	ELI LILLY & Co (LLY)
kisqali femara co-pack	Novartis AG (NVS)
paclitaxel	Mylan II B.V. (MYL)
trodelvy	Immunome Inc. (IMNM)
tykerb	Novartis AG (NVS)
Verzenio®	ELI LILLY & Co (LLY)

Phase 3(21)

Drug	Company
arx788	Ambrx Biopharma Cayman, Inc. (AMAM)
Atirmociclib	Olema Pharmaceuticals, Inc. (OLMA)
AZD2014	ASTRAZENECA PLC (AZN)
Bria-IMT™	BriaCell Therapeutics Corp. (BCTX)
Capivasertib	ASTRAZENECA PLC (AZN)
elacestrant	Radius Health, Inc. (RDUS)
Eribulin	Merus N.V. (MRUS)
Eribulin Mesylate	Merus N.V. (MRUS)
Giredestrant	ENANTA PHARMACEUTICALS INC (ENTA)
GnRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
goserelin	Novartis AG (NVS)
Goserelin	Novartis AG (NVS)
lasofoxifene	LeonaBio, Inc. (LONA)
LHRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
Palazestrant	Olema Pharmaceuticals, Inc. (OLMA)
palazestrant (formerly known as OP-1250)	Olema Pharmaceuticals, Inc. (OLMA)
palazestrant (OP-1250)	Olema Pharmaceuticals, Inc. (OLMA)
PF-07220060 CDK4 inhibitor	Merus N.V. (MRUS)
SYS6010	Merus N.V. (MRUS)
tesetaxel	Odonate Therapeutics, Inc. (ODT)
Vinorelbine Tartrate	Merus N.V. (MRUS)

Phase 2(4)

Drug	Company
ad-rts-hil-12	Alaunos Therapeutics, Inc. (TCRT)
ngc-cap	Processa Pharmaceuticals, Inc. (PCSA)
Tocilizumab	Merus N.V. (MRUS)
veledimex	Alaunos Therapeutics, Inc. (TCRT)

Phase 1(10)

Drug	Company
Alpelisib	Olema Pharmaceuticals, Inc. (OLMA)
Atirmociclib	Merus N.V. (MRUS)
Denosumab	Aclaris Therapeutics, Inc. (ACRS)
elacestrant	STEMLINE THERAPEUTICS INC (STML)
Empagliflozin	Merus N.V. (MRUS)
Inavolisib	Merus N.V. (MRUS)
Selicrelumab	Merus N.V. (MRUS)
SGN-LIV1A	Merus N.V. (MRUS)
Zoledronic acid	Aclaris Therapeutics, Inc. (ACRS)
Zumsemetinib	Aclaris Therapeutics, Inc. (ACRS)

Phase 1/Phase 2(1)

Drug	Company
ryz101	RayzeBio, Inc. (RYZB)

BioSniper tracks 47 drugs in development for Metastatic Breast Cancer across 23 companies.

There are 59 clinical trials targeting Metastatic Breast Cancer tracked by BioSniper.

The estimated prevalence of Metastatic Breast Cancer is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.